Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These companies spend a significant amount in advancing their pipelines. One such biopharma company is Coronado Biosciences, Inc. (CNDO) whose pipeline includes TSO (trichuris suis ova or CNDO-201) and CNDO-109.
Recently, Coronado Biosciences commenced a study evaluating TSO for the treatment of pediatric patients with autism spectrum disorder (:ASD). This is an investigator initiated study conducted by the Hadassah-Hebrew University Medical Center in Jerusalem, Israel.
The randomized, double-blind, placebo-controlled, 16-week study (n=60) among patients in the age group of 6-17 years will evaluate the safety of TSO in pediatric patients with ASD as compared to placebo. The patients will receive placebo, 2500 TSO or 7500 TSO every other week.
TSO is currently under development for the treatment of autoimmune diseases, such as, Crohn’s disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, type I diabetes and rheumatoid arthritis. In Dec 2013, Coronado Biosciences submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (:FDA) for the commencement of a phase II study of TSO to treat moderate-to-severe chronic plaque psoriasis
Coronado Biosciences does not have any marketed product in its portfolio. The progress on TSO is encouraging and we expect investor focus to remain on TSO.
Coranado Biosciences carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the biopharma sector may consider companies like Shire (SHPG), Amgen (AMGN) and Alexion Pharmaceuticals, Inc. (ALXN). Alexion and Shire carry a Zacks Rank #2 (Buy) while Amgen holds a Zacks Rank #1 (Strong Buy).